• Publications
  • Influence
Infliximab, azathioprine, or combination therapy for Crohn's disease.
BACKGROUND The comparative efficacy and safety of infliximab and azathioprine therapy alone or in combination for Crohn's disease are unknown. METHODS In this randomized, double-blind trial, weExpand
  • 2,280
  • 80
  • PDF
Infliximab for induction and maintenance therapy for ulcerative colitis.
BACKGROUND Infliximab, a chimeric monoclonal antibody directed against tumor necrosis factor alpha, is an established treatment for Crohn's disease but not ulcerative colitis. METHODS TwoExpand
  • 2,207
  • 74
  • PDF
Infliximab maintenance therapy for fistulizing Crohn's disease.
BACKGROUND Infliximab, a monoclonal antibody against tumor necrosis factor, is an effective maintenance therapy for patients with Crohn's disease without fistulas. It is not known whether infliximabExpand
  • 1,827
  • 71
Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.
OBJECTIVE--To assess the safety and efficacy of a preparation of mesalazine (5-aminosalicylic acid) coated with a pH dependent resin (Eudragit L) as compared with sulphasalazine in patients withExpand
  • 923
  • 60
  • PDF
Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis.
BACKGROUND & AIMS We tested whether the attenuation of experimental colitis by live probiotic bacteria is due to their immunostimulatory DNA, whether toll-like receptor (TLR) signaling is required,Expand
  • 851
  • 25
  • PDF
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.
BACKGROUND & AIMS This analysis of Crohn's disease patients treated with infliximab in ACCENT I compared episodic and scheduled treatment strategies under conditions that simulate clinical practice.Expand
  • 894
  • 24
A Simple Classification of Crohn's Disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998
Summary: Crohn's disease is a heterogeneous entity. Previous attempts of classification have been based primarily on anatomic location and behavior of disease. However, no uniform definition ofExpand
  • 1,118
  • 23
Toll-like receptor 9-induced type I IFN protects mice from experimental colitis.
Experimental colitis is mediated by inflammatory or dysregulated immune responses to microbial factors of the gastrointestinal tract. In this study we observed that administration of Toll-likeExpand
  • 388
  • 21
  • PDF
Enhanced colonic nitric oxide generation and nitric oxide synthase activity in ulcerative colitis and Crohn's disease.
Recent studies have suggested that nitric oxide (NO.), the product of nitric oxide synthase in inflammatory cells, may play a part in tissue injury and inflammation through its oxidative metabolism.Expand
  • 347
  • 16
  • PDF
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab.
BACKGROUND & AIMS The efficacy of infliximab for treating patients with ulcerative colitis has been established. METHODS The Active Ulcerative Colitis Trial (ACT)-1 and ACT-2 randomized,Expand
  • 395
  • 13
  • PDF